Skip to content
    TARS
    Earnings call· Jun 2026(Q2 FY26)

    Tarsus Pharmaceuticals Q2 FY26 earnings call TARS

    Aug 6, 2026 Source

    Executive summary

    Tarsus Pharmaceuticals Q2 FY26 — Record XDEMVY Sales and Strategic Acquisition of Alkeus Pharmaceuticals

    Tarsus Pharmaceuticals reported a strong second quarter, driven by record sales of XDEMVY, which continues to exceed expectations and is on track for over $2 billion in potential annual peak sales. The company also announced the strategic acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease, to its retina pipeline. This move broadens Tarsus's presence in the retina specialty, leveraging XDEMVY's commercial success to fund future growth and build a leading eye care company with multiple potential blockbuster medicines.

    Highlights

    5

    • XDEMVY net product sales reached a record $173.9 million, representing over 69% year-over-year growth and 20% quarter-over-quarter growth.

    • Full-year XDEMVY net product sales guidance was raised to $685 million to $705 million from $670 million to $700 million.

    • More than 700,000 patients have been treated with XDEMVY to date, generating almost $1 billion in net product sales.

    • XDEMVY retreatment rates advanced into the high teens, with expectations to stabilize at 20%.

    • Unaided awareness of Demodex blepharitis (DB) climbed to approximately 30%, up from 2% at launch, driven by effective consumer campaigns.

    Concerns

    2

    • The increase in full-year R&D expense guidance to $190 million-$210 million (from $115 million-$135 million) reflects the upfront consideration for the iRenix Medical acquisition.

    • The Alkeus acquisition involves an upfront consideration of $450 million ($270 million cash, $180 million stock) and up to $350 million in potential milestones, impacting near-term cash and stock dilution.

    Guidance & targets

    6
    CategoryTargetConfidence
    XDEMVY Full-Year Net Product Sales
    $685 million to $705 million
    high materiality
    High
    Gross Margins
    approximately 93%
    medium materiality
    High
    SG&A Expenses
    $545 million to $565 million
    medium materiality
    High
    R&D Expense
    $190 million to $210 million
    high materiality
    High
    ALK-001 NORTHSTAR Phase III Top-Line Results
    Second half of 2029
    high materiality
    High
    Profitability
    Sometime in '27
    medium materiality
    Medium

    Operational metrics

    13
    XDEMVY Net Product Sales
    $173.9 million69% YoY growth, 20% QoQ growth
    Q2 FY26

    Record net product sales for the quarter.

    Gross Margins
    93%flat
    Q2 FY26

    Consistent with expectations.

    Cash, Cash Equivalents, and Marketable Securities
    $449.7 million
    Q2 FY26 end

    Balance at the end of the second quarter.

    XDEMVY Patients Treated
    700,000+
    to date

    Cumulative number of patients treated with XDEMVY since launch.

    XDEMVY Net Product Sales (Cumulative)
    $1 billion
    to date

    Cumulative net product sales for XDEMVY since launch.

    ECPs Prescribing XDEMVY (near daily cadence)
    doubled
    past year

    Indicates increasing adoption and integration into standard of care.

    XDEMVY Retreatment Rates
    high teensadvancing
    Q2 FY26

    Maturing as expected, indicating sustained demand.

    Unaided Awareness of Demodex Blepharitis
    30%up from 2% at launch
    Q2 FY26

    Significant increase driven by consumer campaigns.

    XDEMVY.com Website Engagement
    19%increase
    Q2 FY26

    Reflects increased patient education and motivation to seek care.

    Estimated US Stargardt Disease Patients
    86,000
    current

    Total estimated patient population for ALK-001.

    ALK-001 Clinical Trial Exposure
    400+
    to date

    Demonstrates favorable tolerability profile.

    ALK-001 Phase III NORTHSTAR Enrollment Target
    230
    ongoing

    Enrollment target for the NORTHSTAR study.

    Retina Sales Force Size (new assets)
    50 to 75
    future

    Planned size for a dedicated sales force to support new retina assets like ALK-001 and IRX-101.

    Industry KPIs

    6
    MetricValueDetails
    Peak sales guidance$2 billion+USD
    EPS revenue guidance$685 million to $705 millionUSD
    Product franchise net sales$173.9 millionUSD
    Pipeline clinical milestonesNORTHSTAR Phase III study
    Clinical trial efficacy safety datavisual function preservation, slow retinal atrophy
    Business development capacity deal appetite$449.7 millionUSD

    Deals & partnerships

    2
    Alkeus PharmaceuticalsAcquisition of Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease.$450 million upfront ($270 million cash, $180 million Tarsus common stock) plus up to $350 million in potential milestones (regulatory approval, first commercial sale) and low single-digit tiered decreasing royalties on future net sales.

    The transaction is subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Tarsus secured $125 million through a private placement financing from a syndicate of leading health care investors, including several shareholders of Alkeus.

    iRenix MedicalAcquisition of iRenix Medical, adding a product to the pipeline.$75 million upfront consideration (reflected in increased R&D guidance).

    The acquisition was completed prior to the Alkeus announcement and is part of Tarsus's strategy to expand its pipeline and leadership in eye care.

    Risks & headwinds

    3
    Seasonal revenue progression for XDEMVYQ3 and Q4 FY26

    Tempered growth expected in Q3 FY26, followed by more robust growth in Q4 FY26.

    Mitigation: Management's full-year guidance already accounts for this seasonality, which includes fewer physician office visits due to vacations, holidays, and conferences in the summer period, and usual year-end patient dynamics.

    Integration risk and financial impact of Alkeus acquisitionNear-term and long-term

    Upfront consideration of $450 million ($270 million cash, $180 million stock) and up to $350 million in potential milestones.

    Mitigation: Tarsus is investing from a position of strength with a robust balance sheet and maintaining financial flexibility. The transaction is expected to close later this year, subject to regulatory approvals. A private placement financing of $125 million was secured to support the acquisition.

    Competitive landscape for Stargardt diseaseOngoing

    Competitor (Belite's tinlarebant) has a head start in Phase III trials.

    Mitigation: Tarsus believes ALK-001's differentiated profile (efficacy in atrophy and low-light visual acuity, strong safety profile without impacting visual cycle) will allow it to capture significant market share. The NORTHSTAR trial is already enrolling globally and is expected to be well underway by the time other products might be approved.

    What to watch in Q3 FY26

    5

    XDEMVY Q3 Revenue Progression

    Q3 FY26
    CurrentQ2 FY26 net product sales: $173.9 million
    TargetTempered growth due to seasonality

    Why it matters

    To assess if XDEMVY's quarterly revenue progression aligns with management's expectation of seasonality (tempered Q3, robust Q4) within the raised full-year guidance.

    As we have previously discussed, we expect the quarterly revenue progression throughout the remainder of the year to reflect normal seasonality in the eye care market. The summer period typically includes fewer physician office delayed case due to vacations, holidays and conferences, and we expect tempered growth in the [Technical Difficulty].

    Q&A highlights

    5

    How does ALK-001 compare in efficacy to tinlarebant, especially given its head start? What are the differentiating factors for market share?

    ALK-001 offers a unique profile by demonstrating effectiveness in slowing disease progression measured by atrophy and low-light visual acuity, coupled with a strong safety profile over 7 years. Its mechanism reduces toxic dimers without impacting the visual cycle, which is crucial for patients, and it has shown no negative effects on night vision or color vision. Management believes this differentiation makes it a $1 billion+ opportunity.

    “So in terms of overall profile, we see something that can really change the course of this disease that demonstrated effectiveness in a couple of dimensions that are really important patients, both the progression of disease is measured by atrophy and the progression of disease measured by visual acuity, low-light visual acuity in particular. And that's unique in this field.”

    asked by Ryan Ries · answered by Bobak Azamian

    3 min read6 chapters

    Detailed Narrative

    01

    XDEMVY Commercial Momentum and Market Penetration

    XDEMVY continues to demonstrate exceptional commercial performance, with Q2 net product sales reaching $173.9 million, marking a 69% YoY and 20% QoQ growth. The company has treated over 700,000 patients to date, generating nearly $1 billion in net product sales. Eye care professionals (ECPs) are increasingly adopting XDEMVY, with the number of ECPs prescribing at a near-daily cadence doubling over the past year. Retreatment rates are advancing into the high teens, expected to stabilize at 20%, indicating sustained demand for the product.

    02

    Strategic Acquisition of Alkeus Pharmaceuticals and ALK-001

    Tarsus announced the acquisition of Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease. This acquisition broadens Tarsus's presence in the retina specialty, complementing the earlier acquisition of IRX-101. ALK-001 is positioned to become a foundational treatment for Stargardt disease, a devastating inherited retinal disease with no FDA-approved treatments, affecting an estimated 86,000 patients in the US.

    03

    ALK-001 Clinical Profile and Market Opportunity

    ALK-001 is a modified vitamin A analog designed to slow the formation of toxic vitamin A dimers, which cause Stargardt disease, while preserving the normal visual cycle. Clinical evidence from TEASE studies showed potential to preserve visual function and acuity, slow retinal atrophy, and demonstrated a favorable long-term tolerability profile over 7 years in more than 400 patients. The ongoing NORTHSTAR Phase III study aims to confirm these benefits, with top-line results expected in H2 2029. Management estimates ALK-001 represents a $1 billion+ opportunity, with potential pricing in the $350,000 range.

    04

    Commercial Strategy for Retina Portfolio

    Tarsus plans to apply its commercial execution playbook to the new retina assets, focusing on a more concentrated physician base of approximately 3,500 retina specialists. The strategy involves delivering strong scientific evidence, securing broad access, and launching efficiently. There are anticipated synergies in the sales force, as a subset of the 500 doctors treating IRX-101 patients are also expected to prescribe Stargardt therapies. The company is considering a dedicated sales force of 50-75 individuals for the new retina assets.

    05

    Consumer Engagement and Awareness for XDEMVY

    Tarsus's consumer campaigns, featuring celebrity spokesperson John Cena and the 'Barry the Cat' DTC campaign, have significantly increased unaided awareness of Demodex blepharitis to 30%. Website engagement on XDEMVY.com has increased by 19%, with patients actively using tools like 'Find a Doctor' and the AI-powered concierge. These efforts are successfully driving patients to seek care and ask for XDEMVY by name, reinforcing the top of the funnel for market expansion.

    06

    Financial Outlook and Capital Allocation

    Tarsus ended Q2 with $449.7 million in cash, cash equivalents, and marketable securities. The company increased its full-year XDEMVY net product sales guidance to $685 million-$705 million. Full-year R&D expense guidance was raised to $190 million-$210 million due to the iRenix acquisition, while SG&A and gross margin expectations remain consistent. The Alkeus acquisition, valued at $450 million upfront plus milestones, is financed through cash and stock, with an additional $125 million from a private placement, demonstrating disciplined capital allocation to strengthen the long-term growth profile.

    AI-generated summary of the company’s earnings call. Not investment advice.